Hepatitis with cholestatic jaundice occurs most frequently as an adverse reaction to the following preparation of erythromycin:
**Question:** Hepatitis with cholestatic jaundice occurs most frequently as an adverse reaction to the following preparation of erythromycin:
A. Erythromycin base
B. Erythromycin ethylsuccinate
C. Erythromycin stearate
D. Erythromycin lactobionate
**Core Concept:**
Erythromycin is a macrolide antibiotic that is available in various formulations, each with different pharmacokinetic and pharmacodynamic properties. Hepatitis and cholestatic jaundice are rare but potentially severe adverse reactions associated with erythromycin use.
**Why the Correct Answer is Right:**
Erythromycin base (A) is a pure antibiotic form without any additives or excipients that may contribute to the risk of hepatic toxicity. The other options contain additional components that could potentially harm the liver, making them less suitable for individuals at risk for liver disease or those with a history of liver issues.
**Why Each Wrong Option is Incorrect:**
- Erythromycin ethylsuccinate (B) contains succinic acid, which may cause cholestasis and further damage the liver.
- Erythromycin stearate (C) includes stearic acid as an excipient, which can lead to cholestasis and liver toxicity.
- Erythromycin lactobionate (D) contains lactobionic acid, a potential hepatotoxic agent, contributing to the elevated risk of hepatitis and cholestasis.
**Clinical Pearl:**
When selecting erythromycin preparations for patients with pre-existing liver issues or those on long-term antibiotic therapy, consider erythromycin base (Option A) due to its reduced risk of liver toxicity compared to other formulations. This decision aids in preventing severe adverse reactions and ensures patient safety.